Arcutis Biotherapeutics Hits New 52-Week High of $21.55

Arcutis Biotherapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 21.55 on October 8, 2025. This achievement underscores the company's remarkable performance over the past year, with a staggering 181.7% increase compared to the S&P 500's 17.88% gain during the same period.
The company has demonstrated strong financial metrics, including a notable growth in net sales of 164.13%, reflecting its robust operational performance. Arcutis has reported positive results for the last seven consecutive quarters, showcasing its ability to maintain momentum in a competitive market.

Despite being a loss-making entity, the company has maintained a high institutional ownership rate of 100%, indicating strong confidence from institutional investors. Additionally, the stock's price-to-book ratio stands at 14.97, while its debt-to-equity ratio is at -0.60, further illustrating its financial positioning.

With a 52-week low of USD 8.03, the stock's recent performance highlights its significant upward trajectory, marking a pivotal moment for Arcutis Biotherapeutics, Inc. in the biotechnology landscape.